Program
TQB2029
A development code. Also written as “TQB2029 injection”.
In Sino Biopharmaceutical's pipeline, GPRC5D/CD3双抗
. Its studies are mostly in Multiple Myeloma, led by Sino Biopharmaceutical.
Furthest: phase 1, since Nov 20, 20241 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Nov 20, 2024 | Nov 20, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2029
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2024First study: phase 1 study in Multiple MyelomaFirst studyNCT06700395 · 136 planned · China
TargetBeta
“GPRC5D/CD3双抗”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 3 |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 2 |
| MBS314 for Injectionrule | beijing-mabworks-biotech-co-ltd | phase 2 | 1 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06700395Multiple Myeloma · China | 1 | Recruiting | Mar 2026 | 136 |
How it is read
Names in the registry
- “TQB2029 injection”, 1 entry
Codes read as this program: TQB2029.
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.